RINGER'S IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RINGER'S IN PLASTIC CONTAINER (RINGER'S IN PLASTIC CONTAINER).
Ringer's solution is an isotonic crystalloid that replaces extracellular fluid volume and electrolytes. Lactate in lactated Ringer's is metabolized to bicarbonate in the liver, providing a buffer source.
| Metabolism | Lactate metabolized to bicarbonate in liver (for lactated Ringer's); electrolytes are excreted unchanged by kidneys. |
| Excretion | Ringer's solution components are excreted renally: sodium (98% reabsorbed, 2% excreted), chloride (99% reabsorbed, 1% excreted), potassium (90% reabsorbed, 10% excreted), calcium (98% reabsorbed, 2% excreted), and lactate (metabolized to bicarbonate, then renally excreted as CO2 and water). Essentially 100% of administered water and electrolytes are eliminated via kidneys. |
| Half-life | Not applicable as Ringer's solution does not have a terminal elimination half-life in the traditional sense; its components (water, electrolytes) are continuously regulated by renal and hormonal mechanisms. The half-life of infused lactate is approximately 10-20 minutes, but this is not a drug half-life. |
| Protein binding | None; electrolytes (sodium, potassium, calcium, chloride, lactate) are not significantly protein-bound. Free fraction is 100%. |
| Volume of Distribution | The volume of distribution of water is approximately 0.6 L/kg (total body water). Electrolytes distribute throughout the extracellular fluid (0.2 L/kg) for sodium and chloride, with potassium distributing into intracellular fluid. However, as a solution, the Vd is that of water, ~0.6 L/kg. |
| Bioavailability | Intravenous: 100% (directly into systemic circulation). Subcutaneous: bioavailability is approximately 70-80% due to local metabolism and delayed absorption. Not administered orally. |
| Onset of Action | Intravenous: immediate upon infusion, with plasma volume expansion occurring within minutes. Subcutaneous: onset within 30-60 minutes due to slower absorption. |
| Duration of Action | Intravenous: duration of volume expansion is transient, lasting 1-2 hours post-infusion as fluid redistributes and is excreted. Electrolyte effects persist until renal excretion. Subcutaneous: duration of action is prolonged, up to 4-6 hours for volume effect. |
Intravenous infusion: 500-1000 mL bolus or as needed to replace fluid and electrolyte deficits; rate based on clinical condition.
| Dosage form | INJECTABLE |
| Renal impairment | Use with caution in renal impairment; monitor fluid and electrolyte balance; no specific dose adjustment defined; adjust rate and volume based on renal function and fluid status. |
| Liver impairment | No specific adjustment required; monitor for fluid overload and electrolyte disturbances in severe hepatic impairment. |
| Pediatric use | Intravenous infusion: 20-30 mL/kg bolus for dehydration; maintenance based on body surface area or weight, typically 100-150 mL/kg/day for infants, 120-150 mL/kg/day for children up to 30 kg, then 70-100 mL/kg/day for larger children; adjust according to clinical needs. |
| Geriatric use | Use with caution; lower initial volumes and slower infusion rates due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RINGER'S IN PLASTIC CONTAINER (RINGER'S IN PLASTIC CONTAINER).
| Breastfeeding | Ringer's solution is compatible with breastfeeding. Components are normal constituents of plasma and are present in breast milk at physiological levels. There is no known risk to the nursing infant. M/P ratio: Not applicable as components are endogenous substances with no specific M/P ratio determined. |
| Teratogenic Risk | Ringer's solution is considered safe during all trimesters. There is no evidence of teratogenicity as it is a crystalloid solution containing electrolytes in physiological concentrations. No fetal risks are expected when used as indicated for fluid and electrolyte replacement. |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe hyperkalemia, hypercalcemia (if calcium-containing), metabolic alkalosis, hypoxic lactic acidosis (lactated Ringer's), and known hypersensitivity to any component.
| Precautions | Monitor fluid/electrolyte balance, renal function, and acid-base status. Use with caution in heart failure, renal impairment, hyperkalemia, or lactate metabolism disorders (e.g., hepatic failure). |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs (blood pressure, heart rate, respiratory rate), urine output, serum electrolytes, and fluid balance. In pregnancy, monitor for signs of fluid overload (e.g., edema, pulmonary congestion) and assess fetal heart rate and uterine activity if indicated. |
| Fertility Effects | No known effects on fertility. As a crystalloid solution, it does not alter reproductive function. No studies indicate impairment of fertility. |